



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CPRIT Update and Company Funding Opportunities

Foundations of Cancer Therapeutics Crash Course

August 26, 2021



Cindy R. WalkerPeach, PhD
Chief Product Development Officer

Types of Funding

- **Non-Dilutive and Dilutive**

Non-dilutive funding means you're getting money (capital) without giving up any ownership (equity) of the business.

Dilutive funding means you're getting money (capital) in exchange for ownership (equity) in the business.




Non-Dilutive Funding (Grants!)

- National Cancer Institute (NCI):
Small Business Innovation Research (SBIR)
~\$200 million annually US-wide (3-8%)
- Cancer Prevention & Research Institute of Texas (CPRIT):
Product Development Research (PDR)
~\$75 million annually TX-wide (7-8%)



NCI SBIR



CPRIT: Funding (2007) and Reauthorization (2019)

- 2007 Texans voted overwhelmingly in favor of a constitutional amendment creating the Cancer Prevention and Research Institute of Texas (CPRIT) and funding with \$3 billion in general obligation bonds.
- 2019 A constitutional amendment was approved by Texas voters to authorize an additional \$3 billion in general obligation bond funds on behalf of CPRIT.
- Total is \$6 billion over 20+ years.





CPRIT Grant Award Data

1,679 Awards Totaling \$2.86 Billion

Academic Research

1,371 awards, \$2.06 Billion

Product Development

50 awards, \$493.2 Million

Prevention

258 awards, \$300.3 Million

- 43 companies funded, including 14 relocation companies
- 28 TXCO, 14 RELCO, 8 SEED awards
- 6 companies with multiple awards
- 20 awardee companies conducting active clinical trials

- \$3.82 billion direct follow-on funding raised by companies (> 7 to 1)
- 1100+ jobs created in Texas
- Products launched
 - Belzutifan for cancers associated with von Hippel-Lindau disease** (acquired by Merck)
 - Visualase MRI-Guided Laser Ablation** (acquired by Medtronic)
 - Multiple NGS products** developed/launched by Asuragen (acquired by Bio-Techne)
 - OncologyMAP** developed by RBM (acquired by Myriad, purchased by Q2 Solutions)



Product Development Research Awards

- **Objectives**

- Identifying and funding projects to develop **novel drugs, diagnostic applications, medical devices and other non-traditional products** with focused relevance to **cancer** treatment and prevention
- Funding **Texas-based companies and companies willing to relocate to Texas** that are most likely to bring important products to the marketplace
- Providing funding that promotes the **translation of research at Texas institutions into startup companies** able to compete in the marketplace



Product Development Research Investments

Lubbock




DFW Metroplex



Houston



San Antonio



College Station



Austin



State of Texas University Spin-Outs

Lubbock




San Antonio



College Station



DFW Metroplex



Houston




Austin



Current Product Development Portfolio Mix

AWARD FOCUS



▶ Creating and Expanding Life Science Infrastructure

18 Companies completed IPO or M&A following CPRIT investment



Asuragen[®]
Acquired by Bio-Techne



Acquired by Myriad Genetics



Merged with Synlogic



Acquired by Medtronic



Acquired by iBio




Acquired by Merck



▶ Create and Expand Life Science Infrastructure

Product Development Follow-on Funding



Product Development Award Mechanisms

- **Texas Company Awards (TXCO)**
 - Early-stage companies already located in Texas
 - Up to \$20 million; 3 years
- **Company Relocation Awards (RELCO)**
 - Early-stage companies willing to relocate to Texas
 - Up to \$20 million; 3 years
- **Seed Awards (SEED)**
 - Startup companies; already based in Texas or willing to relocate to Texas
 - Up to \$3 million; 3 years





CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

OncoNano Medicine, Inc.



Leveraging CPRIT Academic Research Funding (before OncoNano Medicine, Inc.)



Jinming Gao, PhD
Professor of Oncology,
Pharmacology and
Otolaryngology
UT Southwestern Medical
Center

Grant ID	Title	Award Date	Amount
RP180343	Turn ON the Tumor Contrast in Lymph Node Metastases for Occult Disease Detection	2018/02/21	\$885,684
RP140140	Turn on the Tumor Contrast for Surgical Resection of Head and Neck Cancers	2014/08/20	\$900,000
RP120897	β -Lapachone Nanotherapeutics for NQO1-Targeted Therapy of Cancer	2012/03/29	\$999,597
RP120094	Turn ON the Tumor Contrast for Surgical Resection of Head and Neck Cancers	2011/11/02	\$965,257
		Total	\$3,750,538



OncoNano Medicine, Inc. (scientific co-founders)



Jinming Gao, PhD
Professor of Oncology,
Pharmacology and
Otolaryngology
UT Southwestern Medical
Center



Baran Sumer, MD
Professor and Chief
Division of Head and Neck Oncology
UT Southwestern Medical Center

Award ID	Date	Title	Amount
DP140072	Aug 2014	OncoNano Medicine: Transforming Cancer Surgery by Tumor Illumination	\$6,000,000
DP190066	Aug 2019	Tumor specific T-cell activating cancer vaccines for immunotherapy of solid tumors including HPV	\$15,427,699
DP200081	Aug 2020	Image-guided Surgical Detection of Metastatic Disease to the Peritoneum, Lymph Nodes and Pleural Surfaces	\$9,965,273
		Total	\$31,392,972



The Invention



www.onconano.com



The Invention



Tian Zhao, PhD
Sr. Director, R&D
OncoNano Medicine, Inc.


www.onconano.com



The Invention



Jinming Gao, PhD
Professor of Oncology, Pharmacology
and Otolaryngology
UT Southwestern Medical Center



Tian Zhao, PhD
Sr. Director, R&D
OncoNano Medicine, Inc.
(former Trainee)

www.onconano.com




OncoNano Medicine, Inc. (ONM-100, Imaging Product)

ONM-100: intraoperative detection of solid cancers

Clinical trial: NCT03735680

Ongoing Phase 2a study to optimize imaging performance of ONM-100 over a range of doses and imaging schedules and explores potential for ONM-100 guided surgery in new tumor types and using additional FDA-approved imaging devices



Product Development Research: RFA Key Dates

FY 2022 Cycle 2

RFA Release Date	November/December 2021
Applications Due	January 2022
Award Notification	August 2022

FY 2023 Cycle 1 (tentative)

RFA Release Date	May/June 2022
Applications Due	August 2022
Award Notification	February 2023





CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Thank you!

Cindy R. WalkerPeach, PhD

Chief Product Development Officer

Cancer Prevention & Research Institute of Texas

P.O. Box 12097 | Austin, Texas 78711 | www.cprit.texas.gov

Direct: 512-305-8419 | Fax: 512-475-2563 | Email: cwalkerpeach@cprit.texas.gov

